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AbstrAct
Objective To estimate the absolute treatment effects 
of newer P2Y12 inhibitors (ticagrelor and prasugrel) 
compared with clopidogrel in men and women with 
acute coronary syndrome (ACS).
Methods We searched Ovid MEDLINE, Embase and 
the Cochrane Central Register of Controlled Trials for 
randomised controlled trials of oral P2Y12 inhibitors 
for acute stroke or ACS. Age-specific and sex-specific 
mortality was obtained for all patients admitted to 
hospital with myocardial infarction in Scotland from 
2006 to 2010 (prior to introduction of prasugrel or 
ticagrelor).
results From 9277 articles, nine fulfilled our inclusion 
criteria. Three trials compared newer P2Y12 inhibitors 
to clopidogrel in ACS, in which the treatment rate ratio 
(RR) for major adverse cardiovascular events in men 
was 0.80 (95% CI 0.69 to 0.93). For the same outcome, 
across all nine trials, the sex–treatment interaction 
RR was 1.08 (95% CI 0.98 to 1.19). Combining these 
estimates yielded a treatment RR in women of 0.86 
(95% CI 0.72 to 1.04). 17 842 women and 27 818 men 
were admitted to hospital with myocardial infarction. 
Mortality was higher for women than men for all-cause 
(5708, 32.0% vs 5891, 21.2%), cardiovascular (4032, 
22.6% vs 4117, 14.8%) and bleeding (193, 1.1% vs 
228, 0.8%) deaths. On applying the sex-specific RRs to 
this population, the absolute risk reduction for mortality 
at 1 year was similar for women and men for all-cause 
(2.30% (95% CI −0.92% to 5.22%) vs 2.47% (95% 
CI 0.62% to 4.10%)), cardiovascular (2.70% (95% 
CI −0.63% to 5.74%)) vs 2.72% (95% CI 0.92% to 
4.35%)) and bleeding (−0.27% (95% CI −1.06% 
to 0.30%) vs −0.18% (95% CI −0.71% to 0.24%)) 
deaths.
conclusion Newer P2Y12 inhibitors may be slightly less 
efficacious in women than men, but the absolute risk 
reduction is similar in both sexes.
bAckgrOund
Despite large falls in cardiovascular mortality over 
the past two decades, overall annual cardiovascular 
mortality rates remain higher for women than for 
men.1 There are important sex differences in the 
pathophysiology, clinical presentation and clinical 
outcomes of women with cardiovascular disease 
compared with men; women with cardiovascular 
disease remain an understudied, underdiagnosed 
and undertreated group.2–4
Oral P2Y12 inhibitors are a mainstay of treatment 
for acute coronary syndrome (ACS). They have 
been evaluated across a broad spectrum of cardio-
vascular disease in several randomised controlled 
trials. Consequently, most clinical guidelines recom-
mend P2Y12 inhibitors for ACS.
5–8
A recent individual-level patient data (IPD) 
meta-analysis compared efficacy of novel P2Y12 
inhibitors for women and men with stable and acute 
coronary artery disease, finding very similar relative 
treatment effects (HRs) for major adverse cardio-
vascular events, bleeding and all-cause mortality.9 
Importantly, the study also presented absolute 
differences in treatment effects in women and men; 
since women experienced a higher baseline risk of 
subsequent cardiovascular events, this meant they 
also received greater overall treatment benefits than 
men.
However, the absolute treatment effects were 
also obtained using the trial data, and people with 
myocardial infarction enrolled in clinical trials are 
on average younger, less frequently hospitalised, 
at lower risk of adverse events and less likely to 
have comorbid disease than people with myocar-
dial infarction identified in disease registers.10 11 
Moreover, the previous review included patients 
treated with intravenous P2Y12 inhibitors during 
elective percutaneous coronary intervention as well 
as patients with stable coronary disease. Conse-
quently, it is not known whether men and women 
experience similar benefits from P2Y12 inhibitors 
following acute hospitalisations for myocardial 
infarction.
The objective of this study is therefore to (1) 
identify whether there exist sex–treatment interac-
tions in the relative efficacy of P2Y12 inhibitors and 
(2) to estimate the effect, in patients typically seen 
in clinical practice, of any such differences on the 
absolute treatment benefits obtained from prasugrel 
or ticagrelor versus clopidogrel.
MethOds
We conducted a systematic review of trials of P2Y12 
inhibitors in men and women and meta-analysed 
these data to produce sex-specific estimates of rela-
tive treatment efficacy for novel P2Y12 inhibitors 
(prasugrel and ticagrelor) in ACS and acute cere-
brovascular disease. We subsequently combined 
these estimates with data on event rates in a target 
population that was not exposed to novel P2Y12 
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inhibitors in order to estimate the absolute treatment effect in a 
real-world population.
Ethical approval was not sought as data were either published 
or were aggregated at country level by the national organisation 
responsible for publishing health outcome data.
systematic review
Search strategy
We searched, without language restriction, using Ovid 
MEDLINE and Embase (from 1946 to 16 July 2017) and the 
Cochrane Central Register of Controlled Trials for: ‘ischaemic 
heart disease’, ‘acute coronary syndrome’, ‘myocardial infarc-
tion’, ‘angina’, ‘stroke’, ‘cerebrovascular disease’, ‘P2Y12 inhib-
itor’, ‘clopidogrel’, ‘prasugrel’, ‘ticagrelor’ and ‘randomised 
controlled trials’ (detailed search strategy in online supple-
mentary appendix). We also hand-searched the bibliography of 
included studies and relevant review articles.
Selection of articles and extraction of data
Studies were included if they met the following inclusion 
criteria: (1) randomised controlled trials of oral P2Y12 inhibitors 
in ACS or stroke and (2) trials providing data on major adverse 
cardiovascular events stratified by sex. We excluded randomised 
controlled trials (RCTs) of intravenous P2Y12 inhibitors and 
RCTs that evaluated different durations of P2Y12 therapy. One 
investigator (KKL) performed initial screening of titles and 
abstracts. A random sample of 200 titles and abstracts were 
assessed during the initial screening process by a second inves-
tigator (AS) without disagreements. Two investigators examined 
the full-text reports for eligibility according to our prespecified 
review protocol. Data extraction was carried out independently 
by KKL and AS and adjudicated by AA.
Definition of outcomes
The clinical outcome examined in this review was the composite 
endpoint ‘major adverse cardiovascular events’ (MACE) reported 
as the primary efficacy endpoint in each individual trial (table 1). 
Outcomes include elements of cardiovascular mortality, all-cause 
mortality, myocardial infarction, stroke (ischaemic or haemor-
rhagic) and occluded infarct-related coronary artery. We also 
examined the safety outcome of bleeding as defined by the indi-
vidual studies that used either standardised Thrombolysis in 
Myocardial Infarction (TIMI) or Global Utilization of Strepto-
kinase and Tissue Plasminogen Activator for Occluded Coronary 
Arteries definitions, or trial specific criteria (table 1).
tArget pOpulAtiOn
NHS National Services Scotland provided data on deaths at 
1 year following a hospital admission with myocardial infarc-
tion from the national linked hospitalisation and death database. 
Myocardial infarction admissions were those assigned a WHO 
10th International Classification of Diseases 10 code (ICD-10) 
of I21 or I22.12 All people in Scotland aged 30–99 years who 
had such an admission during the 5-year time period from 2006 
to 2010 were included. This period was chosen as neither pras-
ugrel nor ticagrelor was available at that time, such that aspirin 
and clopidogrel was the standard treatment for non-ST elevation 
myocardial infarction. Where patients had multiple admissions 
during this period, only the first episode was included.
Deaths were defined as cardiovascular (I00–I99), bleeding 
(see online supplementary appendix) or non-bleeding, non-car-
diovascular deaths. Bleeding codes were selected based on those 
used to identify Bleeding Academic Research Consortium13 
bleeding by the Clinical research using LInked Bespoke studies 
and Electronic health Records group for use in the MINAP data-
base .14 Deaths for which both bleeding and cardiovascular 
codes had been recorded were defined as bleeding deaths for the 
purpose of this analyses.
stAtisticAl AnAlysis
Trials were categorised by indication (ACS or stroke) with ACS 
trials being further split by treatment (newer P2Y12 inhibitors 
vs clopidogrel or clopidogrel vs placebo). We extracted number 
of events and total number randomised for each treatment 
broken down by sex for each trial, fitting a hierarchical gener-
alised linear model with a binomial likelihood and a cumulative 
log–log link. The model estimates relative treatment effects, 
directly comparing greater versus weaker/absent P2Y12 inhibi-
tion (ticagrelor/prasugrel>clopidogrel>placebo), with terms 
for the intercept, sex and treatment, as well as a sex–treatment 
interaction term to allow for sex-specific treatment effects. We 
explored three different models for the interaction: an identical 
interaction for all trials within the drug class, shared interac-
tions between trials within the drug class (using the assumption 
of exchangeability of covariate–treatment interactions within 
drug class15) and shared interactions between trials having 
stratified by indication/treatment. We used the posterior mean 
deviance and deviance information criteria (DIC) to choose 
between models, preferring models with lower values of dbar 
and DIC.
The analysis was run separately for MACE and bleeding 
outcomes. For the MACE outcome, minimally informative 
priors were used. Due to small amounts of data for the bleeding 
outcome, we specified an informative prior to constrain the 
magnitude of the estimated sex–treatment interaction (normal 
distribution, mean=0, SD=0.114), and only ran the shared 
interaction model.
For both MACE and bleeding, sex-specific relative treatment 
effect estimates for prasugrel or ticagrelor versus clopidogrel 
were obtained by combining the overall sex–treatment interac-
tion derived from all included trials with the treatment effect 
in men for trials of prasugrel or ticagrelor versus clopidogrel 
(figure 1A).
The absolute risk reduction (ARR) for women and men was 
obtained by combining these sex-specific relative treatment 
efficacy estimates with baseline risk data for the Scottish popu-
lation (figure 1B). We estimated the baseline rates according 
to age and sex for bleeding deaths, cardiovascular deaths and 
non-bleeding, non-cardiovascular deaths from the Scottish data 
using a generalised linear model with a log-link and multinomial 
distribution to simultaneously estimate the multiple outcomes 
accounting for competing risks. The treatment efficacy rate 
ratios (RRs) from the synthesis of the trial data were used to 
modify the parameters of the baseline risk model to obtain 
ARR estimates. In extensive sensitivity analyses, we varied the 
baseline rates and sex–treatment interactions for MACE and 
bleeding.
All analyses were carried out within a Bayesian framework, 
which meant that combining the estimates from the trial and 
observational data was straightforward.16 Model chains were 
examined graphically to investigate mixing and convergence. 
All analyses were conducted in R (V.3.3.1) and JAGS (V.4.2.0). 
All data and analysis codes are available at (https:// github. com/ 
dmcalli2/ gender_ dapt_ manuscript) with selected code and model 
descriptions provided in the online supplementary material.
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results
systematic review
We assessed the abstracts of 9277 articles identified through 
database searching (online supplement). Forty-one potentially 
relevant articles were reviewed in detail. Of these, we identified 
nine articles that fulfilled our inclusion criteria.17–25
All nine studies were double-blind, randomised-controlled 
trials. CURE, COMMIT and CLARITY-TIMI 28 compared 
clopidogrel with placebo in ACS, CHANCE and SPS3 compared 
clopidogrel with placebo in stroke, SOCRATES compared tica-
grelor with aspirin in stroke and TRITON-TIMI 38, PLATO 
and TRILOGY ACS compared the novel P2Y12 antagonists with 
clopidogrel in ACS. The duration of follow-up ranged from 2 
weeks (COMMIT) to 3 years (SPS3) (table 1).
The average age of patients enrolled was similar across all 
trials (online supplementary appendix). However, women 
were under-represented. In the Scottish population, 39.0% 
(17 842/45 660) of people admitted with myocardial infarction 
were women, whereas only 29.7% (32 561/109 570) of partic-
ipants enrolled overall were women (for each trial, the propor-
tion of women was 19.7%, 26.0%, 27.8%, 28.4%, 33.8%, 
35.9%, and 37.0%, respectively).
Meta-analysis
Sex–treatment interaction
On comparing the three models of sex–treatment interactions 
across all nine trials of P2Y12 inhibitors (figure 2), the model 
assuming a shared sex–treatment interaction for the whole 
drug class had both a lower deviance and DIC than the other 
models (the deviance was 273, 261 and 259 and the DIC was 
291, 289 and 286 for the identical, stratified and shared models, 
respectively), indicating better fit. Consequently, this model was 
preferred.
For this shared-effects model, the RR for the sex–treatment 
interaction was 1.08 (95% credible interval (CI) 0.98 to 1.19, 
figure 3). Similar estimates for the sex–treatment interactions 
were found for the identical (RR 1.09; 95% CI 1.01 to 1.17) and 
stratified (RR for prasugrel/ticagrelor vs clopidogrel comparison 
1.11; 95% CI 0.93 to 1.32) models.
The treatment effect RR in men for the three trials comparing 
prasugrel or ticagrelor to clopidogrel in ACS was 0.80 (95% CI 
0.69 to 0.93). Combining this estimate with the sex–treatment 
interaction estimate from the shared model yielded an RR in 
women of 0.86 (95% CI 0.72 to 1.04). This meant the relative 
risk reduction was approximately 30% lower in women than in 
men.
For bleeding, the sex–treatment interaction RR was 1.04 
(95% CI 0.88 to 1.21). This estimate did not change importantly 
from the moderately informative prior we used in the model-
ling for this outcome (prior for sex–treatment interaction on RR 
scale 1.00; 95% CI 0.80 to 1.25). In men, the treatment effect 
on bleeding was RR 1.13 (95% CI 0.75 to 1.98). As such, the 
modelled treatment effect on bleeding in women was RR 1.18 
(95% CI 0.76 to 2.08).
Figure 1 Overview of data sources used in modelling. Panel A shows the data sources used to estimate the relative treatment efficacy of newer 
P2Y12 inhibitors in women and men and panel B shows the data sources used to estimate the absolute treatment effect. PLATO, Platelet Inhibition and 
Patient Outcomes Trial; TRILOGY ACS, Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes; 
TRITON-TIMI 38, Trial to Assess Improvement in Therapeutic Outcomes by Optimising Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial 
Infarction 38.
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Sex-specific absolute treatment effects in the Scottish population
A total of 17 842 women and 27 818 men were admitted to 
hospital with myocardial infarction. Mortality was higher 
for women than men for all-cause mortality (5708, 32.0% vs 
5891, 21.2%) and cardiovascular mortality (4032, 22.6% vs 
4117, 14.8%). Mortality related to bleeding was also commoner 
in women (193, 1.1% vs 228, 0.8%) deaths. The sex differences 
in cardiovascular mortality differed by age with younger women 
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Figure 2 Relative treatment efficacy for cardiovascular events stratified by sex. Rate ratios and 95% credible intervals estimates of sex-specific 
treatment effects for each trial. Estimates for each trial were estimated independently in generalised linear models. Points represent the point 
estimates, and bars represent the 95% credible intervals. ACS, acute coronary syndrome.
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Figure 3 Relative treatment efficacy for cardiovascular events. Meta-estimates and 95% credible intervals estimates of sex–treatment interactions 
for each trial as well as the overall sex–treatment interaction for P2Y12 inhibitors. All estimates were obtained from generalised linear models. The 
overall sex–treatment interaction was estimated in a hierarchical model. Points represent the point estimates, and bars represent the 95% credible 
intervals. The point-size for each trial is proportional to the inverse of the SE squared for each interaction estimate . The vertices of the diamond 
indicate the 95% credible intervals for the meta-estimate, which was obtained from the ‘shared’ model. ACS, acute coronary syndrome.
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having higher mortality than men and older women having 
lower mortality than men (table 2, figure 4).
Based on our model, the ARR in all-cause mortality at 1 year 
was similar in both sexes. For the 27 818 men admitted to 
hospital with myocardial infarction, the modelled ARR was 
2.72% (95% CI 0.92 to 4.35) for cardiovascular, −0.18% (95% 
CI −0.71 to 0.24) for bleeding and 2.47% (95% CI 0.62 to 
4.10) for all-cause mortality. For the 17 842 women, the ARRs 
were similar, 2.70% (95% CI −0.63 to 5.74) for cardiovas-
cular, −0.27% (95% CI −1.06 to 0.30) for bleeding and 2.30% 
(95% CI −0.92 to 5.22) for all-cause mortality. In contrast with 
the 0.93 probability that relative treatment efficacy is lower in 
women than men, the probability that the ARR for all-cause 
mortality was lower in women than men was only 0.53.
In a subsequent analysis, we modelled the absolute treatment 
effect assuming that the relative treatment effect was the same 
in both sexes. Under this alternative model, a larger benefit 
was seen in women (3.23%; 95% CI 0.84 to 5.41) than in men 
(2.21%; 95% CI 0.56 to 3.72).
table 2 Scotland, mortality at 1 year following hospitalisation for myocardial infarction from 2006 to 2010
Age (years) sex population All cause cardiovascular bleeding Other*
30–39 Female 147 12 (8.2) 8 (5.4) 0 (0.0) 4 (2.7)
Male 507 10 (2.0) 8 (1.6) 0 (0.0) 2 (0.4)
40–49 Female 793 38 (4.8) 22 (2.8) 0 (0.0) 16 (2.0)
Male 2928 105 (3.6) 77 (2.6) 6 (0.2) 22 (0.8)
50–59 Female 1681 137 (8.1) 84 (5.0) 13 (0.8) 40 (2.4)
Male 5513 315 (5.7) 228 (4.1) 18 (0.3) 69 (1.3)
60–69 Female 3109 486 (15.6) 312 (10.0) 13 (0.4) 161 (5.2)
Male 6688 815 (12.2) 563 (8.4) 32 (0.5) 220 (3.3)
70–79 Female 5066 1475 (29.1) 990 (19.5) 48 (0.9) 437 (8.6)
Male 6837 1923 (28.1) 1299 (19.0) 67 (1.0) 557 (8.1)
80–89 Female 5518 2621 (47.5) 1933 (35.0) 91 (1.6) 597 (10.8)
Male 4653 2256 (48.5) 1600 (34.4) 90 (1.9) 566 (12.2)
90–99 Female 1528 939 (61.5) 683 (44.7) 28 (1.8) 228 (14.9)
Male 692 467 (67.5) 342 (49.4) 15 (2.2) 110 (15.9)
All ages Female 17 842 5708 (32.0) 4032 (22.6) 193 (1.1) 1483 (8.3)
Male 27 818 5891 (21.2) 4117 (14.8) 228 (0.8) 1546 (5.6)
Both 45 660 11 599 (25.4) 8149 (17.8) 421 (0.9) 3029 (6.6)
n (%) deaths.
*Non-bleeding, non-cardiovascular.
Figure 4 Baseline risk of death and estimates of the absolute treatment effects of oral P2Y12 inhibition in women and men with myocardial 
infarction in Scotland. Panel A shows estimated risks of deaths obtained from a regression model run on the national Scottish data. A generalised 
linear model with a log-link and multinomial distribution was fitted to all three outcomes (cardiovascular death, bleeding death and non-
cardiovascular, non-bleeding death), which included parameters for age and sex as well as age–sex interactions. Panel B shows the modelled absolute 
risk reduction in this population, obtained from applying to this model the relative treatment efficacy for cardiovascular events and bleeding events 
in men and women. Most patients in the clinical trial data were aged less than 75 years, and we were unable to examine whether treatment effects 
showed heterogeneity by age. As such, estimates for older patients should be treated with caution.
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Age-specific and sex-specific absolute treatment effects
The same pattern was evident when the absolute treatment 
effects were modelled within each age group (figure 4). Assuming 
no age–treatment interaction, much larger ARRs were seen in 
older people than in younger people. For example, the ARR was 
0.20% (95% CI 0.07 to 0.32) and 3.32% (95% CI 1.12 to 5.32) 
in men aged 30–39 and 70–79 years, respectively.
Sensitivity analyses
We modelled the absolute treatment effect for a range of different 
event rates for bleeding deaths in women and men, allowing for 
bleeding rates up to 10-fold higher in men than observed and up 
to twofold higher in women than in men. The point estimate for 
the overall absolute treatment effect in women remained consis-
tently around 2% (range 1.92% to 2.16%).
discussiOn
In a meta-analysis and modelling study using data from 100 000 
participants randomised to P2Y12 inhibitors and over 45 000 
patients from the Scottish population hospitalised with myocar-
dial infarction, we examined relative and absolute treatment 
effects for newer P2Y12 inhibitors.
For relative treatment effects, the results were equivocal, 
although more supportive of P2Y12 inhibitors being less effective 
in women than men. Importantly, however, the baseline risk of 
subsequent cardiovascular death following myocardial infarc-
tion was higher in women. Therefore, in absolute terms, women 
and men had a similar benefit from treatment. Indeed, while 
there was a 93% probability that the relative treatment effect 
was lower in women, the probability for the absolute treatment 
effect being lower was only 53%. This suggests that women are 
likely to experience similar benefits to men when treated with 
newer P2Y12 inhibitors.
There has been considerable interest in differences in treat-
ment effects from P2Y12 inhibitors in women and men, which 
could arise from a range of causes. The spectrum of disease may 
be different; women with myocardial infarction present later 
than men and with different clinical and diagnostic features.4 
Underlying differences in cardiovascular biology have also 
been implicated.26 Women have smaller coronary arteries and 
different carotid anatomy compared with their male counter-
parts.27 Women are also less likely to display thrombogenic 
tendencies, and platelet–subendothelial interactions are mark-
edly reduced following antiplatelet therapy in men compared 
with women.28 Some of these differences are likely to be related 
to the hormonal milieu.26
Nonetheless, previous studies examining variation in relative 
treatment effects for antiplatelet agents have yielded either null 
or small sex–treatment interactions. A previous IPD meta-anal-
ysis of five studies examining the effect of clopidogrel in the 
secondary prevention of cardiovascular disease (including three 
of the studies in our meta-analysis) found that clopidogrel was 
around 1.1-fold less efficacious in women for both cardiovas-
cular events and mortality.29 A more recent IPD meta-analysis 
examining the efficacy of ticagrelor, prasugrel or cangrelor in 
men and women with coronary artery disease (three of the six 
trials were included in our meta-analysis) found no statistically 
significant difference in major adverse cardiovascular events.9 
The report did not include the estimate and CIs for the sex–
treatment interaction. However, we calculated these using the 
published data (see online supplementary material), finding a 
relative difference in HR of 1.00 (95% CI 0.86 to 1.14),9 a range 
which includes our own estimate of 1.08.
One strength of our study over previous meta-analyses is that 
we included additional trials from within the drug class (ie, stroke 
trials and trials comparing clopidogrel with placebo), allowing us 
to more precisely estimate the sex–treatment interactions while 
still allowing for differences by indication and treatment in the 
modelling. However, this approach is unlikely to account for 
the different findings as on restricting the efficacy estimates to 
trials of ticagrelor versus clopidogrel for ACS; we also found a 
1.1-fold difference between men and women. Consequently, the 
most plausible reason for the variation across meta-analyses is 
the difference in included trials.
Nonetheless, in neither our study nor any meta-analysis of 
randomised controlled trials of which we are aware was there a 
difference large enough to outweigh the greater baseline risk in 
women. In the Scottish population, a sex–treatment interaction 
of around 1.2-fold lower efficacy in women would be needed 
for women to have a substantially lower ARR than men. Since 
the treatment effect in men is around 0.80, this amounts to a 
qualitative interaction, that is, an interaction that changes the 
direction of effect not just the magnitude. The risk of cardiovas-
cular mortality following myocardial infarction has been found 
to be higher in woman than men in other settings,1 2 30 to which 
this finding is likely to be applicable.
The assumptions we employed in this modelling study are 
provided in detail in the online supplementary appendix. We 
discuss three important assumptions here. First, we assumed that 
the included trials were sufficiently similar so as to be exchange-
able in terms of sex–treatment interactions. This assumption is, 
we would argue, considerably weaker than the assumption that 
the main effect is consistent across trials. Second, some patients 
admitted to hospital in Scotland with myocardial infarction 
during the 5-year period will not have received dual antiplatelet 
therapy. Nonetheless, in an all-comers trial of diagnostic practice 
in patients with ACS in 2012 in a large region of Scotland, we 
found that 76% of patients received dual antiplatelet therapy.31 
More importantly, as we did not have access to IPD, we could 
not examine heterogeneity in treatment effect by age or by age 
and sex in combination. As such, considerable caution is needed 
in applying these results to older people.
key messages
What is already known on this subject?
Women with myocardial infarction present later than men and 
with different clinical and diagnostic features. Meta-analyses 
comparing the effect of clopidogrel and novel P2Y12 inhibitors 
have not estimated the absolute treatment effects for women 
and men in typical real-world populations.
What might this study add?
This study uses a combination of clinical trial and routine 
healthcare data to show that while P2Y12 inhibitors may be 
slightly less efficacious in women than men, the absolute 
treatment benefit (in terms of the absolute risk reduction) is 
similar in both sexes.
how might this impact on clinical practice?
This study provides reassurance that mere quantitative sex–
treatment interactions (ie, where the magnitude only and not 
the direction of the effect differs between men and women) 
are unlikely to result in women experiencing less benefits from 
secondary prevention than men following myocardial infarction.
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cOnclusiOn
In a meta-analysis and modelling study using data from 100 000 
participants randomised to P2Y12 inhibitors and over 45 000 
patients from the Scottish population hospitalised with myocar-
dial infarction, we have identified that newer P2Y12 inhibitors 
may be slightly less efficacious in women than men but that the 
ARR is similar in both sexes.
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